Precision BioSciences
DTIL
132 hedge funds and large institutions have $337M invested in Precision BioSciences in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 37 reducing their positions, and 14 closing their positions.
117% more call options, than puts
Call options by funds: $2.17M | Put options by funds: $1M
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
16% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 37
1% more funds holding
Funds holding: 131 → 132 (+1)
1.03% less ownership
Funds ownership: 49.98% → 48.95% (-1%)
6% less capital invested
Capital invested by funds: $358M → $337M (-$21M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$4.45M |
| 2 |
JP Morgan Chase
New York
|
+$4.34M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.67M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.39M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$3.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.47M |
| 2 |
Morgan Stanley
New York
|
-$4.29M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.12M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.86M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$2.07M |
DTIL Hedge Fund Activity: Q3 2021 in Review
132 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Precision BioSciences (DTIL) for Q3 2021, worth a combined $337M — down 5.9% from $358M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new DTIL positions and 14 closed out — a net gain of 3 holders — while 43 added to existing stakes and 37 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $4.45M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $7.47M sold.
- 132 institutional investors held Precision BioSciences (DTIL) as of Q3 2021, up from 131 in Q2 2021.
- Funds reported $337M of Precision BioSciences stock for Q3 2021, down 5.9% quarter-over-quarter.
- 17 funds opened new Precision BioSciences positions in Q3 2021 and 14 closed out, a net change of +3 holders.
- The largest Precision BioSciences buyer in Q3 2021 was Goldman Sachs, an estimated $4.45M added.
- The largest Precision BioSciences seller in Q3 2021 was T. Rowe Price Associates, an estimated $7.47M sold.
Based on aggregated 13F filings for Q3 2021.